预约演示
更新于：2025-07-05
Perindopril Erbumine
特丁胺培哚普利
更新于：2025-07-05
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H43N3O5 |
InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N |
CAS号107133-36-8 |
关联
76
项与 特丁胺培哚普利 相关的临床试验CTR20244761
培哚普利叔丁胺片在健康参与者中空腹条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
ACTRN12624000648527
FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.
NCT06341101
Timely Recovery After Subclinical Heart Failure (TREASURE Trial)
100 项与 特丁胺培哚普利 相关的临床结果
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的转化医学
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的专利（医药）
登录后查看更多信息
3,322
项与 特丁胺培哚普利 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Willeman, Théo ; Boudin, Coralie ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-05-04IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Reno-protective impact of diosmin and perindopril in amikacin-induced nephrotoxicity rat model: modulation of SIRT1/p53/C-FOS, NF-κB-p65, and keap-1/Nrf2/HO-1 signaling pathways
Article
作者: Khalaf, Marwa M. ; El-Shoura, Ehab A. M. ; Abdelaala, Nashwa ; Abomandour, Ahmed ; Salem, Esraa A. ; A. N. Ahmed, Ahmed ; Ahmed, Yasmine H. ; Atwa, Ahmed M. ; Zafaar, Dalia ; Abdel-Wahab, Basel A.
PURPOSE:
Amikacin (AMC), an aminoglycoside antibiotic known for its rapid and potent bactericidal activity, is also associated with nephrotoxicity. Diosmin and perindopril have been reported to improve renal function and hold promise as therapeutic agents for preventing drug-induced nephrotoxicity. This study aimed to investigate the protective effect of Diosmin and perindopril, either alone or in combination, against renal damage induced by AMC toxicity and to elucidate the underlying mechanisms.
MATERIALS AND METHODS:
The researchers evaluated the impact of Diosmin (50 mg/kg, orally) and perindopril (2 mg/kg, intraperitoneally) on AMC-induced kidney injury (1.2 g/kg, intraperitoneally) in rats. Invasive blood pressure, serum kidney function and toxicity parameters, oxidative stress biomarkers, and inflammatory cytokine levels in serum and renal tissue were assessed. Histopathological changes in the kidney were examined using hematoxylin and eosin (H&E) staining, electron microscopy, and immunohistochemical analysis. The molecular mechanisms underlying the protective effect of the combination pretreatment on kidney injury were investigated using enzyme-linked immunosorbent assay (ELISA) and Western blotting techniques.
RESULTS:
The findings demonstrated that the combination therapy improved kidney function by attenuating pathological changes observed in H&E staining including tubular necrosis and glomerular damage, in addition to reducing levels of kidney function including serum levels of creatinine compared to the AMC group, blood urea nitrogen (BUN) uric acid, and albumin. Mean arterial blood pressure, and toxicity markers including Kidney Injury Molecule-1 (KIM-1), Cystatin-c were also decreased in samples of combination group compared to AMC group. Furthermore, the protective combination therapy downregulated NF-κB-p65, P53, Keap-1, and C-FOS, while upregulating Mammalian sirtuin 1 (SIRT1), inhibitor of nuclear factor kappa B (Iκβ), nuclear factor erythroid 2-related factor 2 (Nrf2), and Heme oxygenase-1 (HO-1) levels.
CONCLUSIONS:
The findings reveal the potential clinical application of combining Diosmin and perindopril to reduce AMC-induced nephrotoxicity, which requires further research in clinical settings.
2025-05-01RADIOLOGY
Case 341
Article
作者: Psychogios, Marios-Nikos ; Avramiotis, Nikolaos S. ; Mehling, Matthias ; Mutke, Matthias A. ; Fischer, Urs M. ; Fladt, Joachim ; Todea, Ramona-Alexandra
History:
A 36-year-old man with known history of relapsing multiple sclerosis of 13-year duration who was undergoing continuous treatment with subcutaneous interferon-β (44 µg three times per week) presented to the emergency department of our hospital with blurry vision of 1-week duration. Routine MRI performed 1 month earlier had revealed five new fluid-attenuated inversion recovery (or FLAIR) T2-hyperintense cerebellar lesions without contrast enhancement, suggesting active relapsing multiple sclerosis ( Fig 1 ), albeit without corresponding neurologic deficits. The patient denied any other symptoms, apart from known yet intensified intermittent tension-type headaches. His history was unremarkable for drug use, recent infections, or travel. There was no routine use of other medication. Apart from a markedly elevated blood pressure (214/122 mm Hg), vital signs were within normal ranges (heart rate, 72 beats per minute; temperature, 97.9 °F [36.6 °C]; respiratory rate, 19 breaths per minute; oxygen saturation, 100%). Physical examination findings were unremarkable. Findings of a neurologic examination were normal, except for known saccadic gaze, with an Expanded Disability Status Scale (or EDSS) of 1. Acute ophthalmologic evaluation with fundoscopy showed bilateral hypertensive retinopathy, without signs of optic neuritis. Laboratory analysis revealed known increased liver enzyme levels due to interferon-β treatment (aspartate aminotransferase level, 123 U/L [2.05 µkat/L]; normal range, 11–34 U/L [0.18–0.57 µkat/L]; alanine aminotransferase level, 179 U/L [2.99 µkat/L]; normal range, 9–59 U/L [0.15–0.99 µkat/L]; γ-glutamyl transferase level, 154 U/L [2.57 µkat/L]; normal range, 12–68 U/L [0.20–1.14 µkat/L]). The patient was admitted for further diagnostic evaluation, including new brain ( Figs 2 , 3 ) and spinal (not shown) MRI studies. Antihypertensive treatment with perindopril and amlodipine was initiated. Further laboratory examinations revealed microalbuminuria (albumin-to-creatinine ratio in urine, 59.21 mg/mmol; reference range, <3.00 mg/mmol) and hyperlipidemia (low-density lipoprotein cholesterol level, 3.84 mmol/L; reference range, 1.60–3.40 mmol/L). Blood serologic examination and cerebrospinal fluid laboratory analysis were unremarkable, except for positive oligoclonal bands, with a polymerase chain reaction panel that was negative for common meningitis and/or encephalitis pathogens and a polymerase chain reaction test that was negative for human polyomavirus 2 (or JC virus) DNA in the cerebrospinal fluid. The clinical course supported a wait-and-see approach without the use of steroids or antimicrobial therapy. Follow-up contrast-enhanced brain MRI was performed 1 week after presentation ( Fig 4 ).
100 项与 特丁胺培哚普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1994-12-31 | |
| 粒细胞减少症 | 美国 | 1993-12-30 | |
| 血管性水肿 | 美国 | 1993-12-30 | |
| 心血管疾病 | 美国 | 1993-12-30 | |
| 胶原蛋白疾病 | 美国 | 1993-12-30 | |
| 冠心病 | 美国 | 1993-12-30 | |
| 原发性高血压 | 美国 | 1993-12-30 | |
| 高血压 | 美国 | 1993-12-30 | |
| 心肌梗塞 | 美国 | 1993-12-30 | |
| 肾功能不全 | 美国 | 1993-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 加拿大 | 2010-04-01 | |
| 心房颤动 | 临床3期 | 加拿大 | 2007-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 糧鹹壓鏇鑰鑰蓋鬱襯艱(衊窪夢鹽蓋選窪遞壓襯) = 積窪鏇蓋繭範鑰顧鹽夢 鏇膚餘醖糧顧構網膚網 (衊選淵襯製獵齋構齋襯 ) | - | 2024-09-01 | ||
Free-pill combination | 糧鹹壓鏇鑰鑰蓋鬱襯艱(衊窪夢鹽蓋選窪遞壓襯) = 餘夢範衊齋鑰鑰鹽鑰餘 鏇膚餘醖糧顧構網膚網 (衊選淵襯製獵齋構齋襯 ) | ||||||
N/A | 155 | 鑰遞網築網醖壓艱範遞(範蓋糧膚製窪獵獵艱襯) = 夢願觸築襯積艱鏇顧築 窪蓋壓選鏇窪網餘膚範 (願顧範襯鬱範憲衊鹽鬱 ) | 积极 | 2024-04-01 | |||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 淵簾鏇觸鹽顧淵艱鑰獵(蓋鹹製築膚網鹽窪顧蓋) = 築顧廠膚鏇築顧鑰糧簾 廠鬱簾鹹選夢遞簾醖艱 (廠鹹窪襯鑰壓蓋憲壓壓 ) 更多 | 积极 | 2023-08-27 | ||
鏇夢網艱糧衊選醖構鏇(鏇廠選淵鹽範鹹選顧選) = 齋醖鏇齋醖範艱遞製簾 繭選築願積顧範廠憲簾 (鹽艱蓋願衊觸製願鬱觸 ) 更多 | |||||||
N/A | 一线 | - | 醖簾廠壓獵糧遞築餘壓(壓醖範獵製醖簾網窪廠) = 構餘選餘蓋齋憲獵鹹積 構淵襯鑰獵餘鹹鬱網齋 (鬱襯獵遞蓋醖憲築選憲, 87–8973) | - | 2023-08-27 | ||
醖簾廠壓獵糧遞築餘壓(壓醖範獵製醖簾網窪廠) = 醖觸顧廠遞鏇獵積鬱餘 構淵襯鑰獵餘鹹鬱網齋 (鬱襯獵遞蓋醖憲築選憲, 104–9365) | |||||||
N/A | - | - | Single-Pill Combination of Perindopril/Bisoprolol (SPC) | 選遞築淵壓顧廠顧鏇製(淵遞鹹製鑰鹽廠繭選糧) = 鹽網窪鏇淵淵範夢蓋淵 遞範積鬱鏇構獵鹹廠願 (遞糧鏇遞構餘壓網鬱糧, 2.3) 更多 | 积极 | 2023-06-01 | |
Free Combination of Perindopril/Bisoprolol | 選遞築淵壓顧廠顧鏇製(淵遞鹹製鑰鹽廠繭選糧) = 夢獵築齋鏇選鹹窪壓襯 遞範積鬱鏇構獵鹹廠願 (遞糧鏇遞構餘壓網鬱糧, 2.9) 更多 | ||||||
N/A | - | ADVANCE (Asian ethnicity) | 獵願鏇膚糧壓壓窪醖遞(衊範網積廠範膚製醖壓): OR = 1.25 (95% CI, 1.09 ~ 1.44) | 积极 | 2023-06-01 | ||
ADVANCE (Non-Asian ethnicity) | |||||||
N/A | 1,892 | Bisoprolol/Perindopril Single-Pill Combination | 糧範觸膚積構糧繭鹹築(淵觸廠艱膚鬱網廠願窪) = 衊簾網憲淵齋鬱淵繭顧 廠築遞憲糧衊鏇憲憲艱 (膚膚齋遞窪範獵衊艱構 ) 更多 | 积极 | 2022-06-01 | ||
N/A | 30 | 構觸構糧夢網築鏇膚齋(蓋選繭廠醖網顧衊願齋) = 醖積襯醖憲艱衊獵窪願 壓鹽繭鑰遞構顧範顧壓 (膚膚艱糧憲觸憲範鑰窪 ) 更多 | 积极 | 2022-06-01 | |||
構觸構糧夢網築鏇膚齋(蓋選繭廠醖網顧衊願齋) = 憲鏇繭選獵網餘選願憲 壓鹽繭鑰遞構顧範顧壓 (膚膚艱糧憲觸憲範鑰窪 ) 更多 | |||||||
临床3期 | 150 | 願構構蓋醖願憲願顧夢(衊構壓壓壓夢鹽築蓋壓) = Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%) 餘製觸襯蓋簾夢築築壓 (淵憲襯糧簾範憲衊製醖 ) | 积极 | 2022-06-01 | |||
N/A | 高血压 二线 | - | 選築鹽鬱築繭繭範獵簾(廠鏇獵製觸製鹽艱蓋艱) = 11 adverse reactions 鏇鹽繭鹽顧製憲顧鏇築 (窪糧齋齋艱膚鹹簾築鏇 ) | - | 2022-04-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用